PT-141

---

PT-141, also known as Bremelanotide, is a synthetic peptide analog of α-Melanocyte-Stimulating Hormone (α-MSH) and a melanocortin receptor agonist.

Unlike Melanotan II, which primarily affects skin pigmentation, PT-141 is researched for its potent effects on sexual arousal and neuroendocrine signaling through direct action on the central nervous system rather than vascular pathways.

It is one of the first peptides designed to target sexual desire and function at the brain level, not the bloodstream — making it a leading compound in libido and neuro-hormonal research.

PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, areas responsible for regulating sexual behavior, motivation, and energy homeostasis.

Key mechanisms observed in research:

1. Enhances dopamine activity – increases sexual desire and arousal
    
2. Acts centrally – independent of nitric oxide or vascular mechanisms
    
3. Stimulates MC4R receptors – triggers libido and performance pathways
    
4. Modulates energy & mood – supports hypothalamic balance and reward signaling
    
5. Non-specific gender effect – observed in both male and female models
    

Sexual arousal

Increased libido and sexual motivation

Performance research

Enhanced erectile and orgasmic response

Mood balance

Supported dopamine-serotonin homeostasis

Energy metabolism

Mild fat-burning and appetite regulation effects

CNS activity

Improved neuro-hormonal communication

Injectable (subcutaneous)

0.5–2.0 mg

30–60 min before observed effect

Intranasal (experimental)

2–6 mg total dose

Single administration

Combined with MT-2

Lower dose (≈0.5 mg)

For synergistic receptor activation

• Half-life: ~2 hours
   
• Onset (research observation): 30–60 minutes
   
• Duration: up to 6–12 hours (dose-dependent)
   
• Cycle duration (research): short, on-demand administration